Table 1. Clinical and pathological data related to PD-L1 and PD1 expression.
| N = 36 (100%) | PD-L1- n (%) | PD-L1+ n (%) | p-value | PD1- n (%) | PD1+ n (%) | p-value |
|---|---|---|---|---|---|---|
| Age | 0.69 | 0.47 | ||||
| ≤60 | 2 (5,6) | 9 (25) | 3 (8,3) | 8 (22,2) | ||
| >60 | 7 (19,4) | 18 (50) | 11 (30,6) | 14 (38,9) | ||
| Gender | 0.65 | 0,67 | ||||
| M | 1 (2,8) | 6 (16,7) | 5 (13,9) | 2 (5,6) | ||
| F | 8 (22,2) | 21 (58,3) | 16 (44,4) | 13 (36,1) | ||
| pT | 0.13 | 0.51 | ||||
| T1 | 1 (2,8) | 0 (0) | 1 (2,8) | 0 (0) | ||
| T2 | 5 (13,9) | 8 (22,2) | 7 (19,4) | 5 (13,9) | ||
| T3 | 3 (8,3) | 15 (41,7) | 12 (33,4) | 7 (19,4) | ||
| T4 | 0 (0) | 4 (11,1) | 1 (2,8) | 3 (8,3) | ||
| pN | 1 | 0,74 | ||||
| N0 | 5 (13,9) | 14 (38,9) | 8 (22,3) | 11 (30,5) | ||
| N1&N2 | 4 (11,1) | 13 (36,1) | 6 (16,7) | 11 (30,5) | ||
| Stage | 0.26 | 0.95 | ||||
| I | 3 (8,3) | 2 (5,5) | 2 (5,5) | 3 (8,3) | ||
| II | 3 (8,3)) | 12 (33,4) | 5 (13,9) | 10 (27,8) | ||
| III | 3 (8,3) | 11 (30,6) | 6 (16,7) | 8 (22,2) | ||
| IV | 0 (0) | 2 (5,6) | 1 (2,8) | 1 (2,8) | ||
| Visceral pleura invasion | 0.055 | 1 | ||||
| PL0 | 7 (19,4) | 10 (27,8) | 10 (27,8) | 7 (19,4) | ||
| PL1, 2 &3 | 2 (5,6) | 17 (47,2) | 12 (3,4) | 7 (19,4) | ||
| Histopathological subtype | 1 | 0.36 | ||||
| Pleomorphic carcinoma | 8 (22,2) | 23 (63,9) | 11 (30,6) | 20 (55,5) | ||
| Other subtypes | 1 (2,8) | 4 (11,1) | 3 (8,3) | 2 (5,6) | ||
| TTF-1 and/or Napsin A immunohistochemistry | 0.039 | 0.47 | ||||
| Negative | 0 (0) | 10 (27,8) | 11 (30,6) | 14 (38,9) | ||
| Positive | 9 (25,0) | 17 (47,2) | 3 (8,3) | 8 (22,2) | ||
| p40 | 0.013 | 0.68 | ||||
| Negative | 4 (11,1) | 24 (66,7) | 10 (27,8) | 18 (50,0) | ||
| Positive | 5 (13,9) | 3 (8,3) | 4 (11,1) | 4 (11,1) | ||
| Predominant component | 0.27 | 1 | ||||
| Sarcomatoid component | 4 (11,1) | 18 (50,0) | 9 (25,0) | 13 (36,1) | ||
| Non-sarcomatoid component | 5 (13,9) | 9 (25,0) | 5 (13,9) | 9 (25,0) | ||
| Giant cell component | 0.23 | 0.48 | ||||
| Present | 4 (11,1) | 19 (52,8) | 12 (33,3) | 11 (30,6) | ||
| Absent | 5 (13,9) | 8 (22,2) | 9 (25,0) | 4 (11,1) | ||
| EGFR or BRAF or HER2 or PIK3CA mutation | 0.15 | 0.39 | ||||
| Absent | 7 (19,4) | 16 (44,5) | 8 (22,2) | 15 (41,6) | ||
| Present | 0 (0) | 7 (19,4) | 1 (2,8) | 6 (16,7) | ||
| Impossible | 2 (5,6) | 4 (11,1) | 5 (13,9) | 1 (2,8) |